EIF2A and neoplasm: The ATP citrate lyase inhibitor BMS-303141 triggers the p-eIF2α/ATF4/CHOP axis, synergizing with sorafenib to suppress tumor growth [123], whereas 125I brachytherapy combined with lobaplatin amplifies apoptosis via the same pathway [124].